Atara Biotherapeutics, Inc.

ATRA

NASDAQ · Biotechnology

$8.56

At close - Sep 23, 4:00 PM EDT - USD

Market Cap$77M

P/E3.3x

52W High$19.15

Volume40.47K

VCP Research Verdict2026Q1

Revenue Collapse Exposes Critical Liquidity Solvency Risks

Atara Biotherapeutics faces a precarious outlook as its reliance on non-recurring milestone payments has resulted in a severe revenue contraction from $98.1 million in 2025Q1 to $516.0K in 2026Q1. The company's inability to establish a sustainable commercial m...

GrowthContracting

ProfitabilityNegative

ValuationAttractive

TechnicalsWeak

Explore valuation models

MARKET ACTION

ATRA price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

ATRA-51.83%

S&P 500 (^GSPC)+12.39%

1-Year Return

ATRA-34.00%

S&P 500 (^GSPC)+15.77%

3-Year Return

ATRA-78.99%

S&P 500 (^GSPC)+82.11%

5-Year Return

ATRA-98.02%

S&P 500 (^GSPC)+68.16%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y Low

3.3x

Forward P/E

N/A

EV/EBITDA0th %ile

3.2x

FCF YieldCash Flow

N/A

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

3.3x

7.0x

0th· Low

EV/EBITDA

3.2x

7.2x

0th· Low

Price/FCF

N/A

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend

Revenue

$121M-6.3% YoY

Net income

$33M+138.3% YoY

Free cash flow

-$51M+26.1% YoY

Operating margin

29.7%+94.4 pts YoY

ROIC (TTM)462.6%

Avg ROIC 5Y-

ROE (TTM)-

Piotroski Score4 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate9/12 (75%)

Revenue Beat Rate7/12 (58%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Aug 11, 2026	-$0.32-1.6% vs -$0.32	$630,000+14.5% vs $550,000
Q2 2026 May 14, 2026	-$0.29+12.0% vs -$0.33	$516,000-82.2% vs $3M
Q2 2026 May 12, 2026	-$0.29+12.0% vs -$0.33	$516,000-82.2% vs $3M
Q2 2026 Mar 16, 2026	-$0.25-177.8% vs -$0.09	$2M-51.2% vs $3M

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

1 Stories

Business Wire·Aug 12, 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the.

Filtered for Atara Biotherapeutics, Inc.More Headlines

Compare before deciding

Benchmark ATRA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Atara Biotherapeutics, Inc. (ATRA)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ATRAAtara Biotherapeutics, Inc.Current	$8.56	$77.13M	3.33	-6.33%	27.07%	—	—
FATEFate Therapeutics, Inc.	$2.43	$283.24M	-2.11	-51.24%	-1941.09%	-65.08%	—
ADCTADC Therapeutics S.A.	$1.31	$166.62M	-1.17	14.85%	-123.03%	—	—
CABACabaletta Bio, Inc.	$2.22	$361.98M	-1.35	—	—	-128.27%	—
IMVTImmunovant, Inc.	$34.54	$7.13B	-12.47	—	-7585.86%	-69.59%	—
RCUSArcus Biosciences, Inc.	$26.39	$3.32B	-8.02	-4.26%	-386.32%	-87.98%	—

Compare ATRA vs Peers

Atara Biotherapeutics, Inc. (ATRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for ATRA.

Scale Benchmark

vs AMGN

Larger-name benchmark to compare ATRA against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, ADCT, CABA, IMVT

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ATRA SEC Filings & Documents

Atara Biotherapeutics, Inc. (ATRA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Aug 12, 2026·SEC

Material company update

Jun 26, 2026·SEC

Material company update

Jun 12, 2026·SEC

10-K Annual Reports

FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 7, 2025·SEC

10-Q Quarterly Reports

FY 2026

Aug 12, 2026·SEC

FY 2026

May 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

Get notified when ATRA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ATRA Frequently Asked Questions

Atara Biotherapeutics, Inc. (ATRA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Atara Biotherapeutics, Inc.'s revenue?

Atara Biotherapeutics, Inc. (ATRA) reported $6.2M in revenue for fiscal year 2025.

How fast is Atara Biotherapeutics, Inc. growing?

Atara Biotherapeutics, Inc. (ATRA) saw revenue decline by 6.3% over the past year.

Is ATRA profitable?

Atara Biotherapeutics, Inc. (ATRA) reported a net loss of $16.7M for fiscal year 2025.

Dividend & Returns

What is Atara Biotherapeutics, Inc.'s free cash flow?

Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $21.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ATRA back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Aug 11, 2026

-$0.32-1.6%

vs -$0.32

$630,000+14.5%

vs $550,000

Q2 2026

May 14, 2026

-$0.29+12.0%

vs -$0.33

$516,000-82.2%

vs $3M

Q2 2026

May 12, 2026

-$0.29+12.0%

vs -$0.33

$516,000-82.2%

vs $3M

Q2 2026

Mar 16, 2026

-$0.25-177.8%

vs -$0.09

$2M-51.2%

vs $3M

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

ATRAAtara Biotherapeutics, Inc.Current

$8.56

$77.13M

3.33

-6.33%

27.07%

—

FATEFate Therapeutics, Inc.

$2.43

$283.24M

-2.11

-51.24%

-1941.09%

-65.08%

—

ADCTADC Therapeutics S.A.

$1.31

$166.62M

-1.17

14.85%

-123.03%

—

CABACabaletta Bio, Inc.

$2.22

$361.98M

-1.35

—

-128.27%

—

IMVTImmunovant, Inc.

$34.54

$7.13B

-12.47

—

-7585.86%

-69.59%

—

RCUSArcus Biosciences, Inc.

$26.39

$3.32B

-8.02

-4.26%

-386.32%

-87.98%

—